(Total Views: 629)
Posted On: 10/07/2024 5:38:37 PM
Post# of 148863
Very positive CEO comments indeed.
And perhaps we can expound upon what was released on September 24. Dr J. made it clear that he wants to explore other potential synergies. To me, that means he's not waiting for Madigral Pharma to come a knocking, while also making it clear he desires to support other therapeutics. Perhaps something is already in the works. I suspect there is. Sometimes I imagine turning on the Poker Channel and seeing Dr. J at the final table (lol)!
“These initial results are very exciting and confirm our belief that leronlimab has the potential to be materially beneficial for patients suffering from a number of medical concerns,” said Dr. Jacob Lalezari, CEO of CytoDyn. “While additional research is necessary to confirm and explore these findings further, we are very encouraged about the potential for leronlimab to support therapeutics meant to address MASH and specifically fibrosis and related complications in the liver.”
CytoDyn is in discussions with SMC Laboratories regarding next steps – including supplemental lab studies to expand on these promising findings, further explore potential synergies and continue to advance the Company’s clinical pipeline.
And perhaps we can expound upon what was released on September 24. Dr J. made it clear that he wants to explore other potential synergies. To me, that means he's not waiting for Madigral Pharma to come a knocking, while also making it clear he desires to support other therapeutics. Perhaps something is already in the works. I suspect there is. Sometimes I imagine turning on the Poker Channel and seeing Dr. J at the final table (lol)!
“These initial results are very exciting and confirm our belief that leronlimab has the potential to be materially beneficial for patients suffering from a number of medical concerns,” said Dr. Jacob Lalezari, CEO of CytoDyn. “While additional research is necessary to confirm and explore these findings further, we are very encouraged about the potential for leronlimab to support therapeutics meant to address MASH and specifically fibrosis and related complications in the liver.”
CytoDyn is in discussions with SMC Laboratories regarding next steps – including supplemental lab studies to expand on these promising findings, further explore potential synergies and continue to advance the Company’s clinical pipeline.
(7)
(0)Scroll down for more posts ▼
